9 results about "Liver regeneration" patented technology

This invention discloses a double-sided hydrogel with hemostatic, anti-adhesion, and wound repair properties, as well as its preparation and application, belonging to the field of biomedical materials technology. The double-sided hydrogel comprises a repair layer and an anti-adhesion layer. The repair layer is a hydrogel formed by photocuring with OHA, GelMA, AAc, AAc-NHS, and p(APMA-co-THMA) as core components. p(APMA-co-THMA) is obtained by polymerizing THMA and APMA. The anti-adhesion layer is formed by immersing one side of the repair layer in an aqueous solution containing SBMA, GelMA, and MBAA, followed by a thermal cross-linking reaction. The double-sided hydrogel provided by this invention possesses ideal mechanical properties and wet adhesion ability, and exerts anti-inflammatory and wound-healing effects on liver wounds, which can solve the problems of postoperative bleeding, adhesion, and liver regeneration disorders after partial hepatectomy in clinical practice.

The invention provides an application research of nano layered double hydroxides (LDH) for immunoregulation of interleukin-6 (IL-6) to promote liver regeneration, and based on the biomedical potential of the layered double hydroxide nano material, the action mechanism of the layered double hydroxides nano material in liver regeneration is systematically clarified. According to the application, a potential molecular mechanism of promoting liver regeneration by LDH is disclosed for the first time from the perspectives of immunoregulation and signal transduction, and a new theoretical basis and an experimental basis are provided for application of a nano material in tissue regeneration and liver function reconstruction. In the future, physicochemical properties and targeting of LDH can be further optimized, interaction with immune cells, signal transduction network remodeling and long-term safety of LDH can be deeply discussed in combination with a multi-omics technology and an in-vivo imaging means, and a direction is provided for developing novel immunoregulation type nano-drugs.

This invention discloses the application of PIEZO1 inhibitors in the preparation of drugs to inhibit liver regeneration. Specifically, this invention relates to the application of the PIEZO1-specific inhibitor Dooku1 in the preparation of drugs to inhibit liver regeneration after hepatectomy. This invention also provides the application of Dooku1 in the preparation of reagents for constructing animal models of liver aplastic disorder. Experiments of this invention show that administration of Dooku1 significantly reduces the liver weight / body weight ratio, inhibits hepatocyte proliferation (significantly decreasing Ki67 positivity rate), and is accompanied by an increase in serum ALT and AST levels, successfully constructing a target-specific and reproducible animal model of liver aplastic disorder. This invention is the first to apply PIEZO1 inhibitors to inhibit liver regeneration, filling the technological gap in negatively regulating liver regeneration through inhibition of the PIEZO1 pathway, and providing potential candidate drugs and intervention strategies for pathological conditions requiring inhibition of abnormal liver hyperplasia after liver transplantation and hepatectomy.

The application provides application of quinoline-4-carboxylic acid in preparation of anti-aging products and products for protecting liver and promoting liver regeneration, and belongs to the technical field of medicines.The application finds that quinoline-4-carboxylic acid can be used as a novel additive for in-vitro expansion culture of mesenchymal stem cells, breaks the bottleneck of easy aging of mesenchymal stem cells in in-vitro culture, and optimizes the clinical development and application of the mesenchymal stem cells; quinoline-4-carboxylic acid can relieve aging-related phenotypes of fruit flies and mice, enhance the movement ability of fruit flies and the muscle strength of mice, prolong the life span of fruit flies and mice, and is expected to become an effective component of anti-aging therapeutic drugs; quinoline-4-carboxylic acid can improve the survival rate of mice after liver resection, promote liver regeneration after liver resection injury, and is expected to become an effective component of drugs for promoting the prognosis of patients after liver resection, promoting liver regeneration, relieving or treating liver injury and the like.

The invention relates to pyrazolo-pyridine compounds which inhibit mitogen-activated protein kinase kinase 4 (MKK4) and in particular, selectively inhibit MKK4 over protein kinases JNK1 and MKK7. The compounds are useful for promoting liver regeneration or reducing or preventing hepatocyte death. They are further useful for treating osteoarthritis or rheumatoid arthritis, or CNS-related diseases.

The application discloses application of PLIN5 as a target point in development, screening or preparation of a drug for promoting liver regeneration, and the development or screening comprises the following steps: S1, contacting a candidate compound with a cell expressing PLIN5 or a system containing PLIN5 protein; S2, detecting the influence of the candidate compound on the expression level or biological activity of PLIN5; S3, selecting the candidate compound capable of up-regulating the expression level of PLIN5 or enhancing the activity thereof. The application firstly finds that PLIN5 is a key positive regulation target point of liver regeneration, fills the research blank of PLIN5 in the field of liver regeneration regulation in the prior art, and provides a new theoretical basis for the molecular mechanism research of liver regeneration. The up-regulator based on PLIN5 has a clear promoting effect on liver regeneration, can be used for improving the liver function recovery after liver injury, and provides a new drug research and development direction for prevention of postoperative complications of liver resection, treatment of liver fibrosis, alcoholic liver and other diseases.

The present application belongs to the field of food processing and biomedicine, and discloses a gel preparation with anti-hepatic inflammatory aging effect and application thereof. The gel preparation is a gel preparation formed by coating limonin with pectin; the neutral sugar content of the pectin is 15wt%-40wt%, and the methoxyl content is 5wt%-15wt%; and the embedding mass ratio of limonin to pectin is 1:5.5-1:9.5. The gel of the present application realizes the regulation of the embedding amount of limonin through the difference in the neutral sugar content and the methoxyl content of pectin. The gel preparation of the present application significantly improves the inhibitory effect on the inflammatory factor IL-18 and the aging-related protein p21 of hepatic inflammatory aging, and significantly improves the promoting effect on the hepatic regeneration-related protein RB, and reduces the dosage of limonin. The gel preparation of the present application has a synergistic anti-hepatic inflammatory aging effect, and is used for anti-hepatic inflammatory aging drugs, food or dietary supplements.

The application relates to the field of biological medicine, in particular to application of sodium tiglate in preparation of products for promoting liver regeneration and reducing blood ammonia; it is found and disclosed for the first time in the application that sodium tiglate can be applied to preparation of liver regeneration or liver function recovery products, liver cell proliferation capacity of residual liver after partial hepatectomy can be improved by using sodium tiglate, blood ammonia level after liver surgery is controlled, nitrogen metabolism disorder is improved by promoting conversion of blood ammonia into urea, and liver cell regeneration capacity is improved; the application of sodium tiglate provides a new treatment strategy with clear action mechanism and wide development prospect for treatment of insufficient liver regeneration after partial hepatectomy and hyperammonemia.

The application discloses a cirrhosis treatment and liver cancer prevention method based on cMet alpha activation and belongs to the technical field of biological medicine treatment. The method is characterized in that a specific concentration of cMet receptor inhibitors is applied to a cirrhosis patient in a specific time window before and after stem cell transplantation, and cMet-alpha sub-receptors (cMet alpha) in a liver cirrhosis liver are targeted and activated, thus solving the technical problems of liver source shortage in existing liver transplantation, short survival period after stem cell transplantation, difficult long-term effect, and lack of preventive measures in liver cancer treatment. The application can optimize the cirrhosis microenvironment, promote the efficient survival, colonization, liver function differentiation and participation in liver regeneration of transplanted stem cells in the extremely poor microenvironment of cirrhosis, realize the reversal of the cirrhosis course, effectively prevent the progression of cirrhosis to liver cancer, and provide a new and effective way for cirrhosis treatment and liver cancer prevention.